- Home
- KALV vs SBET Comparison
KALV vs SBET Comparison
Compare KALV & SBET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- SBET
- Stock Information
- Founded
- KALV N/A
- SBET 1995
- Country
- KALV United States
- SBET United States
- Employees
- KALV N/A
- SBET N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- SBET Computer Software: Prepackaged Software
- Sector
- KALV Health Care
- SBET Technology
- Exchange
- KALV Nasdaq
- SBET Nasdaq
- Market Cap
- KALV 637.9M
- SBET 618.0M
- IPO Year
- KALV N/A
- SBET 1997
- Fundamental
- Price
- KALV $15.82
- SBET $14.94
- Analyst Decision
- KALV Strong Buy
- SBET
- Analyst Count
- KALV 9
- SBET 0
- Target Price
- KALV $26.29
- SBET N/A
- AVG Volume (30 Days)
- KALV 734.1K
- SBET 46.3M
- Earning Date
- KALV 09-09-2025
- SBET 08-14-2025
- Dividend Yield
- KALV N/A
- SBET N/A
- EPS Growth
- KALV N/A
- SBET N/A
- EPS
- KALV N/A
- SBET N/A
- Revenue
- KALV N/A
- SBET $3,144,153.00
- Revenue This Year
- KALV N/A
- SBET $858.54
- Revenue Next Year
- KALV $221.95
- SBET $194.83
- P/E Ratio
- KALV N/A
- SBET N/A
- Revenue Growth
- KALV N/A
- SBET N/A
- 52 Week Low
- KALV $7.30
- SBET $2.26
- 52 Week High
- KALV $16.32
- SBET $124.12
- Technical
- Relative Strength Index (RSI)
- KALV 71.16
- SBET 37.44
- Support Level
- KALV $13.72
- SBET $19.01
- Resistance Level
- KALV $13.96
- SBET $20.27
- Average True Range (ATR)
- KALV 0.69
- SBET 1.48
- MACD
- KALV 0.31
- SBET -0.50
- Stochastic Oscillator
- KALV 99.15
- SBET 9.31
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About SBET SharpLink Gaming Ltd.
SharpLink Gaming Inc is a online technology company that connects sports fans, leagues and sports websites to relevant and timely sports betting content. The company owns a performance marketing platform through which the company owns and operates state-specific web domains designed to attract, acquire, and drive local sports betting and casino traffic directly to its sportsbook and casino partners which are licensed to operate in each respective state. The company has one operating segment: Affiliate Marketing Services, which operates in United States and Rest of the world. The company generates the majority of the revenue earned from the Affiliate Marketing Services in Rest of the world.